https://doi.org/10.4081/ejh.2022.3423

Lobetyolin suppressed lung cancer in a mouse model by inhibiting epithelial-mesenchymal transition

Vol. 66 No. 3 (2022)
Submitted: 19 April 2022
Accepted: 24 June 2022
Published: 4 July 2022
Lobetyolin, lung cancer, cisplatin, epithelial-mesenchymal transition, Chinese traditional medicine
Abstract Views: 1215
PDF: 604
HTML: 51
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Lu Liu
lil382st@gmail.com
https://orcid.org/0000-0001-8864-4262
Center for Clinical Drug Research and Development, The First Hospital of Qiqihar, Qiqihaer, Heilongjiang, China.
Zhankui Liu
Center for Clinical Drug Research and Development, The First Hospital of Qiqihar, Qiqihaer, Heilongjiang, China.
Liu Yang
Center for Clinical Drug Research and Development, The First Hospital of Qiqihar, Qiqihaer, Heilongjiang, China.
Xue Wu
Center for Clinical Drug Research and Development, The First Hospital of Qiqihar, Qiqihaer, Heilongjiang, China.
Jiaying Zhu
Center for Clinical Drug Research and Development, The First Hospital of Qiqihar, Qiqihaer, Heilongjiang, China.
Lili Liu
Center for Clinical Drug Research and Development, The First Hospital of Qiqihar, Qiqihaer, Heilongjiang, China.
Yang Liu
Center for Clinical Drug Research and Development, The First Hospital of Qiqihar, Qiqihaer, Heilongjiang, China.

Traditional Chinese medicines are gaining more attention as promising adjuvant agents for conventional chemotherapy. Recent studies have shown that lobetyolin (LBT) is one of the main bioactive compounds of traditional Chinese medicines and it exhibits anticancer activity in several types of cancer. Therefore, this study aimed to investigate the mechanism by which LBT inhibits lung cancer. A549 human lung cancer cells were treated with LBT. In addition, A549 cells were injected into Balc/b nude mice to establish model of lung cancer. The mice were treated with cisplatin (DDP) or LBT alone or in combination, and tumor growth was monitored. Protein levels of E-cadherin, vimentin and matrix metalloproteinase 9 (MMP9) were detected. We found that the combination of LBT and DDP showed stronger effect to inhibit the proliferation of A549 cells compared to LBT or DDP treatment alone. Wound healing assay showed that the ratio of wound healing was significantly lower in LBT group and DDP group and was the lowest in LBT+DDP group. Transwell invasion assay showed that the invasion ability of A549 cells was the weakest in LBT+DDP group. Protein levels of E-cadherin were the highest while those of vimentin and MMP9 were the lowest in A549 cells treated with LBT+DDP. Nude mouse xenograft tumor model showed that the combination of LBT with DDP had the highest efficacy to inhibit the growth of lung cancer, and tumor tissues of mice treated with LBT+DDP had the lowest expression of vimentin and MMP9 and the highest expression of E-cadherin. In conclusion, LBT significantly enhances the efficacy of chemotherapy on lung cancer, and the mechanism may be related to the inhibition of epithelial-mesenchymal transition.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Wang J, Wang Y, Tong M, Pan H, Li D. Research progress of the clinicopathologic features of lung adenosquamous carcinoma. Onco Targets Ther 2018;11:7011-7. DOI: https://doi.org/10.2147/OTT.S179904
Zhang D, Tong LX, Wang QJ, Cao YF, Gao Y, Yang DH, et al. Diagnosis of lung cancer based on plasma metabolomics combined with serum markers. Oncologie 2020;22:75-82. DOI: https://doi.org/10.32604/oncologie.2020.012376
Dempke WC. Targeted therapy for NSCLC -- A double-edged sword? Anticancer Res 2015;35:2503-12.
Hadda T B, Kamaruddin M, Patel S. Reversal of multidrug resistance and antitumor promoting activity of 3-oxo-6β-hydroxy- β-amyrin isolated from Pistacia integerrima. Biocell 2021;45:139–47. DOI: https://doi.org/10.32604/biocell.2021.013277
Cao C, Han D, Su Y, Ge Y, Chen H, Xu A. Ginkgo biloba exocarp extracts induces autophagy in Lewis lung cancer cells involving AMPK / mTOR / p70S6k signaling pathway. Biomed Pharmacother 2017;93:1128-35. DOI: https://doi.org/10.1016/j.biopha.2017.07.036
Cao DD, Xu HL, He AB, Xu XM, Ge W. The effect of ShenQi FuZheng injection in combination with chemotherapy versus chemotherapy alone on the improvement of efficacy and immune function in patients with advanced non-small cell lung cancer: A meta-analysis. PLoS One 2016;11:e0152270. DOI: https://doi.org/10.1371/journal.pone.0152270
Xu R, Lin L, Li Y, Li Y. ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis. PLoS One 2017;12:e0185254. DOI: https://doi.org/10.1371/journal.pone.0185254
Wei D, Wang L, Chen Y, Yin G, Jiang M, Liu R, et al. Yangyin Fuzheng Decoction enhances anti-tumor efficacy of cisplatin on lung cancer. J Cancer 2018;9:1568-74. DOI: https://doi.org/10.7150/jca.24525
Bailly C. Anticancer properties of lobetyolin, an essential component of Radix Codonopsis (Dangshen) Nat Prod Bioprospect 2021;11:143–53. DOI: https://doi.org/10.1007/s13659-020-00283-9
Wang J, Tong X, Li P, Cao H, Su W. Immuno-enhancement effects of Shenqi Fuzheng injection on cyclophosphamide-induced immunosuppression in Balb/c mice. J Ethnopharmacol 2012;139:788-95. DOI: https://doi.org/10.1016/j.jep.2011.12.019
He W, Tao W, Zhang F, Jie Q, He Y, Zhu W, et al. Lobetyolin induces apoptosis of colon cancer cells by inhibiting glutamine metabolism. J Cell Mol Med 2020;24:3359-69. DOI: https://doi.org/10.1111/jcmm.15009
Wang MC, Wu YF, Yu WY, Yu B, Ying HZ. Polyacetylenes from Codonopsis lanceolata root induced apoptosis of human lung adenocarcinoma cells and improved lung dysbiosis. Biomed Res Int 2022;2022:7713355. DOI: https://doi.org/10.1155/2022/7713355
Phan NHT, Thuan NTD, Hien NTT, Huyen PV, Duyen NHH, Hanh TTH, et al. Polyacetylene and phenolic constituents from the roots of Codonopsis javanica. Nat Prod Res 2022;36:2314-20. DOI: https://doi.org/10.1080/14786419.2020.1833200
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. DOI: https://doi.org/10.1016/j.cell.2011.02.013
Chen X, Zhang H, Li L, Chen W, Bao T, Li B. miR-5100 mediates migration and invasion of melanomatous cells in vitro via targeting SPINK5. J Compr Mol Sci Genet 2021;1:14-23.
Cao L, Yang DM, Bai B. Mir-1247 affects the proliferation, invasion and apoptosis of osteosarcoma cells through SOX9. Oncologie 2021;23:149-58. DOI: https://doi.org/10.32604/oncologie.2021.014151
Bassiouni W, Ali MAM, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J 2021;288:7162-82. DOI: https://doi.org/10.1111/febs.15701
Chen X, Deng L, Jiang X, Wu T. Chinese herbal medicine for oesophageal cancer. Cochrane Database Syst Rev 2016;(1):CD004520. DOI: https://doi.org/10.1002/14651858.CD004520.pub7
He XR, Han SY, Li XH, Zheng WX, Pang LN, Jiang ST, et al. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo. J Ethnopharmacol 2017;204:45-57. DOI: https://doi.org/10.1016/j.jep.2017.04.008
Sun Q, Yuan M, Wang H, Zhang X, Zhang R, Wang H, et al. PKM2 is the target of a multi-herb-combined decoction during the inhibition of gastric cancer progression. Front Oncol 2021;11:767116. DOI: https://doi.org/10.3389/fonc.2021.767116
Yang G, Hao X, Hu J, Dong K, Xu H, Yang L, et al. Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL). J Natl Cancer Cent 2021;1:139. DOI: https://doi.org/10.1016/j.jncc.2021.08.001
Zhong J, Li X, Wang Z, Duan J, Li W, Zhuo M, et al. Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. J Natl Cancer Cent 2021;1:153. DOI: https://doi.org/10.1016/j.jncc.2021.11.001
Zhang S, Lv X, Li L, Luo Y, Xiang H, Wang L, et al. Melittin inhibited glycolysis and induced cell apoptosis in cisplatinresistant lung adenocarcinoma cells via TRIM8. Biocell 2021;45:167-75. DOI: https://doi.org/10.32604/biocell.2021.013636
Gu F, Zhang J, Yan L, Li D. CircHIPK3/miR-381-3p axis modulates proliferation, migration, and glycolysis of lung cancer cells by regulating the AKT/mTOR signaling pathway. Open Life Sci 2020;15:683-95. DOI: https://doi.org/10.1515/biol-2020-0070

Ethics Approval

The animal use protocol has been reviewed and approved by the Animal Care and Use Committee of The First Hospital of Qiqihar, China (No. 072564)

How to Cite

Liu, L., Liu, Z., Yang, L., Wu, X., Zhu, J., Liu, L., & Liu, Y. (2022). Lobetyolin suppressed lung cancer in a mouse model by inhibiting epithelial-mesenchymal transition. European Journal of Histochemistry, 66(3). https://doi.org/10.4081/ejh.2022.3423
Copyright (c) 2022 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

<< < 24 25 26 27 28 29 30 31 32 33 > >> 

You may also start an advanced similarity search for this article.

Publication Facts

Metric
This article
Other articles
Peer reviewers 
3
2.4

Reviewer profiles  N/A

Author statements

Author statements
This article
Other articles
Data availability 
N/A
16%
External funding 
N/A
32%
Competing interests 
N/A
11%
Metric
This journal
Other journals
Articles accepted 
57%
33%
Days to publication 
75
145

Indexed in

Editor & editorial board
profiles
Academic society 
N/A
Publisher 
PAGEPress Publications, Pavia, Italy